-
Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma
Not Recruiting
More
This study is designed to provide evidence of the safety and a preliminary understanding of the efficacy of AME 133v.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 6504935000.
Stanford Investigators
View full details
-
Phase II/III Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma
Not Recruiting
More
This study will compare the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in participants with unresectable or metastatic, relapsed or refractory LMS who have received at least 1 prior line of systemic therapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase II Cabozantinib Combined w/ PD-1 & CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
Not Recruiting
More
The hypothesis of this study is that the response rate of soft tissue sarcoma will be improved with the addition of PD-1 and CTLA-4 inhibition to cabozantinib, and that cabozantinib priming will increase the response to nivolumab and ipilimumab.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase III Randomized Trial of TRC105 and Pazopanib Versus Pazopanib in Advanced Angiosarcoma
Not Recruiting
More
This is a study of TRC105 in combination with standard dose pazopanib compared to single agent pazopanib in patients with angiosarcoma not amenable to curative intent surgery (e.g., metastatic or bulky disease, and disease for which surgical resection would carry an unacceptable risk to the patient) who have not received pazopanib or TRC105 previously.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase II 18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma
Not Recruiting
More
The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patients newly diagnosed with osteosarcoma ("bone cancer").
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase II Regorafenib in Refractory Liposarcoma, Osteogenic Sarcoma, & Ewing/Ewing-Like Sarcomas
Not Recruiting
More
Although regorafenib was approved for use in patients who had progressive GIST despite imatinib and/or sunitinib on the basis of phase II and phase III data, it has not been examined in a systematic fashion in patients with other forms of sarcoma.
Given the activity of sorafenib, sunitinib and pazopanib in soft tissue sarcomas, and evidence of activity of sorafenib in osteogenic sarcoma and possibly Ewing/Ewing-like sarcoma, there is precedent to examine SMOKIs (small molecule oral kinase inhibitors) such as regorafenib in sarcomas other than GIST. It is also recognized that SMOKIs (small molecule oral kinase inhibitors)such as regorafenib, sorafenib, pazopanib, and sunitinib have overlapping panels of kinases that are inhibited simultaneously. While not equivalent, most of these SMOKIs (small molecule oral kinase inhibitors) block vascular endothelial growth factor and platelet derived growth factors receptors (VEGFRs and PDGFRs), speaking to a common mechanism of action of several of these agents.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 650-725-6413.
Stanford Investigators
View full details
-
Phase II Envafolimab +/- Ipilimumab in Advanced or Metastatic UP Sarcoma or Myxofibrosarcoma
Not Recruiting
More
This is a multicenter open-label, randomized, non-comparative, parallel cohort pivotal study of treatment with envafolimab (cohort A and C) or envafolimab combined with ipilimumab (cohort B and D) in patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS)/myxofibrosarcoma (MFS) who have progressed on one or two lines of chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase II Denosumab in Giant Cell Tumor of Bone
Not Recruiting
More
To determine how safe denosumab is in treating subjects with giant cell tumor of bone (GCTB)
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahem, 6507256413.
Stanford Investigators
View full details
-
Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated w/ RCHOP +/- XRT
Not Recruiting
More
This is a multi-center observational study to assess addition of Rituximab in the treatment of previously untreated patients with Diffuse Large B-Cell Lymphomas(DLBCL) over an enrollment period of 60 months. Patients in this study are enrolling for the collection of their data on observations made during normal clinical practice.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 6507256413.
Lead Sponsor
Stanford Investigators
View full details
-
Phase IIb INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Soft Tissue Sarcoma
Not Recruiting
More
This is a phase 2b, randomized, open-label, prospective, multicenter study comparing treatment with INNO 206 to doxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who have not been previously treated with any chemotherapy except potentially as adjuvant or neoadjuvant chemotherapy, and no evidence of tumor recurrence has occurred for at least 12 months.
Stanford is currently not accepting patients for this trial.
For more information, please contact Catherine Norton, 650-723-2868.
Stanford Investigators
View full details
-
Phase III Oral PLX3397 in Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath
Not Recruiting
More
This is a Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called pexidartinib for the treatment of certain tumors for which surgical removal could cause more harm than good.
The main purpose of this study is to gather information about the investigational drug pexidartinib, which may help to treat tumors of pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS).
The study consists of two parts with a follow-up period. In Part 1, eligible study participants will be assigned to receive either pexidartinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Some subjects, assigned to placebo in Part 1 transitioned to pexidartinib for Part 2.
Then a protocol amendment was written to allow only pexidartinib patients to continue into Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label pexidartinib. There was also a follow-up period added to Part 2.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 650-725-6413.
Stanford Investigators
View full details
-
Phase III Eribulin vs Dacarbazine in Soft Tissue Sarcoma
Not Recruiting
More
This is a randomized, open-label, multicenter, Phase 3 study comparing the efficacy and safety of eribulin with dacarbazine in subjects with advanced soft tissue sarcoma who have disease progression within 6 months prior to study enrolment following standard therapies which must have included an anthracycline, unless contraindicated and then at least one additional regimen after failure of the anthracycline.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 6507256413.
Stanford Investigators
View full details
-
Phase I Trametinib in Unresectable or Metastatic Epithelioid Hemangioendothelioma
Not Recruiting
More
This phase II trial studies how well trametinib works in treating patients with epithelioid hemangioendothelioma that has spread to other places in the body (metastatic), nearby tissue or lymph nodes (locally advanced), or cannot be removed by surgery (unresectable). Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Kristen N. Ganjoo, 650-498-7061.
Stanford Investigators
View full details
-
Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
Not Recruiting
More
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the growth of cancer cells by blocking blood flow to the cancer. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with combination chemotherapy may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving bevacizumab together with several chemotherapy drugs (combination chemotherapy) works in treating patients with peripheral T-cell lymphoma or natural killer cell neoplasms.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 6507256413.
Stanford Investigators
View full details
-
Phase 1b/2 AMG 655 + Doxorubicin as 1st Line for Locally Advanced or Metastatic Soft Tissue Sarcoma
Not Recruiting
More
This phase 1/2, multicenter, randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy and safety of AMG 655 when combined with doxorubicin compared with doxorubicin alone in subjects with previously untreated, locally advanced or metastatic, unresectable soft tissue sarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 6507256413.
Stanford Investigators
View full details
-
Phase II Nilotinib in Relapsed/Metastatic PVNS or Diverse-Type Giant Cell Tumor
Not Recruiting
More
Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS). In this research study the investigators are testing whether nilotinib can stop the growth of PVNS or improve the symptoms experienced from PVNS.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 6507256413.
Stanford Investigators
View full details
-
Phase I/II DCC-3014 in Advanced Tumors and Tenosynovial Giant Cell Tumor
Not Recruiting
More
This is a multicenter, open-label Phase 1/2 study of vimseltinib in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2). Phase 1 will enroll both malignant solid tumor and TGCT patients. Phase 2 will comprise two cohorts (Cohort A and Cohort B) and will only enroll TGCT patients.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Trial of Dasatinib in Advanced Sarcomas
Not Recruiting
More
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 6507256413.
Stanford Investigators
View full details
-
Ph 2 Open-label, Two-stage of CC-4047 for Relapsed or Refractory Systemic Anticancer Therapy
More
The purpose of the study is to determine the safety and efficacy of single agent CC-4047 (pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are refractory to prior anticancer therapy.
Stanford Investigators
View full details
-
Phase II Cabozantinib (Dual Inhibitor of MET & VEGFR) in Metastatic Refractory Soft Tissue Sarcoma
Not Recruiting
More
Background:
- Cabozantinib is a cancer treatment drug that blocks the growth of new blood vessels in tumors. It can also block a chemical on tumor cells that allows the cells to grow. A similar drug, pazopanib, is used to treat types of cancer known as sarcomas. Researchers want to see if cabozantinib can be an effective treatment for types of soft tissue sarcoma that have not responded to earlier treatments.
Objectives:
- To test the effectiveness of cabozantinib for soft tissue sarcomas that have not responded to standard treatments.
Eligibility:
- Individuals at least 18 years of age who have soft tissue sarcomas that have not responded to standard treatments.
Design:
* Participants will be screened with a physical exam and medical history. Blood samples will be collected. Imaging studies and other tests will be used to study the tumor before the start of treatment.
* Participants will take cabozantinib tablets daily for 28-day cycles of treatment. The tablets should be taken whole on an empty stomach.
* Treatment will be monitored with frequent blood tests and imaging studies.
* Participants will continue to take cabozantinib for as long as the tumor does not become worse and the side effects are not too severe.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase I MGD009 in Unresectable /Metastatic B7-H3-Expressing Neoplasms
Not Recruiting
More
The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely. Assessments will be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics (PD) and to evaluate potential anti-tumor activity of MGD009.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Drug Interaction Study to Assess the Effect of Pexidartinib on Pharmocokinetics of CYP3A4 and CYP2C9
Not Recruiting
More
This study has two parts.
Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents.
Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types.
In Part 2, the same participants will continue to receive pexidartinib twice daily.
Participants will be allowed to continue using pexidartinib as long as the participant derives benefit.
Stanford is currently not accepting patients for this trial.
For more information, please contact Site Coordinator, 650-723-2868.
Stanford Investigators
View full details
-
Phase II Ipilimumab +Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma
Not Recruiting
More
The purpose of this Phase 2 study is to
1. find out if the study drugs (ipilimumab plus nivolumab) in combination with cryotherapy will help participants with metastatic or locally advanced soft tissue sarcoma;.
2. find out how safe are ipilimumab plus nivolumab given in combination with cryotherapy, and what side effects may be related to treatment.
3. find out how do the study drugs in combination with cryotherapy work in soft tissue sarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 650-498-7061.
Stanford Investigators
View full details
-
Long-Term Follow-Up (LTFU) of Participants Treated with GSK Adoptive Cell Therapies
More
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Stanford Investigators
View full details
-
Phase III Doxorubicin +Olaratumab vs Doxorubicin +Placebo in Advanced/Metastatic Soft Tissue Sarcoma
Not Recruiting
More
The main purpose of this study is to evaluate the efficacy of the combination of doxorubicin plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with advanced or metastatic soft tissue sarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 650-725-6413.
Stanford Investigators
View full details
-
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
Recruiting
More
The primary objective of this phase III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.
Stanford Investigators
View full details
-
Phase II of CMB305 & Atezolizumab in Locally Advanced / Relapsed or Metastatic NY-ESO-1 Sarcoma
Not Recruiting
More
This is an open-label Phase 2 randomized study that will examine the use of the study agents, CMB305 (sequentially administered LV305 which is a dendritic cell-targeting viral vector expressing the New York Esophageal Squamous Cell Carcinoma 1 gene \[NY-ESO-1\] and G305 which is a NY-ESO-1 recombinant protein plus glucopyranosyl lipid adjuvant-stable emulsion \[GLA-SE\]) in combination with atezolizumab or atezolizumab alone, in participants with locally advanced, relapsed or metastatic sarcoma (synovial or myxoid/round cell liposarcoma) expressing the NY-ESO-1 protein.
There is no formal primary hypothesis for this study.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase III TH-302 + Doxorubicin VS Doxorubicin in Locally Advanced Unresectable / Metastatic Sarcoma
Not Recruiting
More
The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact John Ramirez, 6507230387.
Stanford Investigators
View full details
-
Phase I/II FPA008 in Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
Not Recruiting
More
This is a phase 1/2 single arm, open-label, safety, tolerability, and PK study of cabiralizumab in PVNS/dt-TGCT patients.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 650-725-6413.
Stanford Investigators
View full details
-
Phase II Study of Cryoablation and Nirogacestat for Desmoid Tumor
Recruiting
More
The primary purpose of this protocol is Systemic therapy with oral study agent, nirogacestat, followed by a single cryoablation procedure.
Stanford Investigators
View full details
-
Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel
Recruiting
More
The purpose of this expanded access protocol (EAP) is to provide controlled access to Afamitresgene autoleucel, suspension for intravenous infusion that does not meet the commercial release specification (NC afami-cel). This EAP will be conducted at authorized treatment centers where TECELRA® is being administered and where the EAP is approved to be conducted. Patients who are prescribed TECELRA® , sign the informed consent form, and meet all entry criteria will be eligible to participate in this protocol.
Stanford Investigators
View full details
-
Phase 1 Study of Ziftomenib in Combination with Imatinib in Patients with Advanced Gastrointestinal
Recruiting
More
In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.
Stanford Investigators
View full details
-
Phase IIb/III Trabectedin 3-hour or 24-hour Infusion + Doxorubicin in Advanced or Metastatic Sarcoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride and trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether trabectedin is more effective than doxorubicin hydrochloride in treating patients with advanced or metastatic soft tissue sarcoma.
PURPOSE: This randomized phase II/III trial is studying the safety of trabectedin compared with doxorubicin hydrochloride and to see how well they work in treating patients with advanced or metastatic soft tissue sarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 6507256413.
Stanford Investigators
View full details
-
Expanded Access ABI-009 in Advanced PEComa & Malignancy w/ GeneticMutations /mTOR Pathway Activation
Not Recruiting
More
Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients with Advanced Perivascular Epithelioid Cell Tumors (PEComa) and Patients with a Malignancy with Relevant Genetic Mutations or mTOR Pathway Activation
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase II NY-ESO-1-Specific(c259) T Cells +/- OtherAgents in HLA-A2+ w/ NY-ESO-1 &/or LAGE-1a + ST
Not Recruiting
More
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Not Recruiting
More
This is an open-label, single-arm, multi-center, Phase 2 study with Paclitaxel in combination with Bevacizumab in patients with Unresectable or Metastatic Angiosarcoma. The study aims to determine the safety and effectiveness of combining two drugs Paclitaxel and Bevacizumab in the treatment of Angiosarcoma that cannot be removed by surgery, or has spread to other parts of your body. The primary objective is to evaluate 4month non progression rate. The secondary objective is to evaluate overall response rate after 3rd and 6th cycle, median duration of response, 6th and 12th month survival, toxicity of Paclitaxel and Bevacizumab combination, toxicity of maintenance Bevacizumab and to collect paraffin-embedded tumor blocks for angiogenesis markers and tissue microarray.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 650-725-6413.
Lead Sponsor
Stanford Investigators
View full details
-
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
More
In this study, patients with soft tissue sarcoma (STS) will receive ADI-PEG 20 and ifosfamide in combination with radiation as neoadjuvant therapy. In phase I of the study, up to 5 dose levels will be tested to find the recommended phase II dose (RP2D), after which patients enrolling to phase II will be treated at that dose level to assess efficacy.
Stanford Investigators
View full details
-
Phase II Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Not Recruiting
More
This phase II trial studies how well linsitinib works in treating younger and adult patients with gastrointestinal stromal tumors. Linsitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 650-725-6413.
Stanford Investigators
View full details
-
PhaseII CytoreductiveSurgery&HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in UterineLeiomyosarcoma
Not Recruiting
More
The purpose of this study is to find out if giving a dose of heated chemotherapy in the abdomen immediately after surgery that is done to remove uterine leiomyosarcoma type of cancer will help lower the risk of the cancer coming back in the future.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 650-725-6413.
Stanford Investigators
View full details
-
Phase II Nab-Sirolimus in SolidTumors Harboring PathogenicInactivatingAlterations in TSC1/TSC2 Genes
Not Recruiting
More
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Not Recruiting
More
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. All active patients (from both dose-escalation and expansion phases) will then transition into an extension phase.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase III (Atezolizumab vs Placebo) + Cobimetinib & Vemurafenib in Metastatic Melanoma
Not Recruiting
More
This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab + cobimetinib + vemurafenib compared with placebo + cobimetinib + vemurafenib in patients with previously untreated BRAFv600 mutation-positive metastatic or unresectable locally advanced melanoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase IIIa YONDELIS (Trabectedin) or Dacarbazine for Tx of Liposarcoma or Leiomyosarcoma
Not Recruiting
More
The purpose of this study is to evaluate whether overall survival for the trabectedin group is superior to the dacarbazine group for patients with advanced L-sarcoma (liposarcoma or leiomyosarcoma).
Stanford is currently not accepting patients for this trial.
For more information, please contact Catherine Norton, 650723-2868.
Stanford Investigators
View full details
-
Phase II ADP-A2M4 SPEAR T Cells in Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Not Recruiting
More
This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A\*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .
Stanford is currently not accepting patients for this trial.
For more information, please contact Behnaz Parsien, .
Stanford Investigators
View full details
-
Phase III Aldoxorubicin vs Investigator's Choice in Soft Tissue Sarcomas
Not Recruiting
More
The purpose of this study is to determine the efficacy and safety of aldoxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 650-725-6413.
Stanford Investigators
View full details
-
Phase II Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
Not Recruiting
More
The outcome of patients with metastatic Ewings Sarcoma is poor with current standard of care chemotherapy, with less than 30% survival. Based on recent encouraging pediatric literature we have designed this trial to improve the outcome of patients with metastatic Ewings sarcoma using Irinotecan and Temozolomide in addition to standard chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 650-725-6413.
Lead Sponsor
Stanford Investigators
View full details
-
Phase II Pazopanib in Imatinib & Sunitinib Intolerant Gastrointestinal Stromal Tumors
Not Recruiting
More
This study is being done to gather information about the safety (any harmful effects) and effectiveness (usefulness) of Pazopanib in the treatment of Gastrointestinal Stroma Tumors (GIST) that cannot be treated by surgery or has spread to other organs. The Food and Drug Administration (FDA) have approved Pazopanib for the treatment of advanced kidney cancer but it is not approved for the treatment of GIST. The investigators hope to learn about the safety and usefulness (effectiveness) of Pazopanib for patients with GIST.
Primary Objective:
Non-progression rate based on RECIST criteria (CR+PR+SD)
Secondary Objectives:
* Response per Choi criteria
* 6 month progression-free survival
* Safety and tolerability
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 6507256413.
Stanford Investigators
View full details
-
Phase I/II TH-302 in Combination with Doxorubicin for Advanced Soft Tissue Sarcoma
Not Recruiting
More
The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Advanced Soft Tissue Sarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 6507256413.
Stanford Investigators
View full details
-
Phase III DCC-2618 vs Sunitinib in Advanced Gastrointestinal Stromal Tumors after Tx w/ Imatinib
Not Recruiting
More
This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to ripretinib 150 mg once daily (continuous dosing for 6 week cycles) or sunitinib 50 mg once daily (6 week cycles, 4 weeks on, 2 weeks off).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Prospective Eval of Outcomes of Radiosurgical Treatment of NSCLC
Not Recruiting
More
The purpose of this study is to assess the short and long-term outcomes after CyberKnife stereotactic radiosurgery for early stage non-small cell lung cancer (NSCLC) in patients who are medically inoperable.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
Phase II ABI-009 in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)
Not Recruiting
More
A phase 2 multi-center investigation of efficacy of nab-sirolimus (formerly known as ABI-009 or nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumor (PEComa).
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 650-725-6413.
Stanford Investigators
View full details
-
Phase II/III Selinexor (KPT-330) vs Placebo in Advanced Unresectable Dedifferentiated Liposarcoma
Not Recruiting
More
This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 342 total patients will be randomized to study treatment (selinexor or placebo).
Stanford is currently not accepting patients for this trial.
For more information, please contact Kristen Ganjoo, MD, .
Stanford Investigators
View full details
-
Phase III DCC-2618 In AdvanCed Gastrointestinal Stromal TUmorS w/ Tx w/ Prior Anticancer Therapies
Not Recruiting
More
This is a 2-arm, randomized, placebo-controlled, double-blind, international, multicenter study comparing the efficacy of ripretinib (DCC-2618) to placebo in patients who have received treatment with prior anticancer therapies. Prior anticancer therapies must include imatinib, sunitinib, and regorafenib (3 prior therapies). Approximately 120 patients were randomized in a 2:1 ratio to ripretinib 150 mg QD or placebo
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
